[Immunotherapy of recurrent respiratory infections. Double-blind study of a new immunomodulator in 60 patients].
A new immunomodulator, SLO4 oral drops, was tested for treatment and prevention of recurrent respiratory infections in a double-blind, drug versus placebo trial conducted in 60 adults with chronic bronchitis or asthma. This agent brought about a highly significant reduction in the frequency and duration of infectious episodes, as well as a decrease in antibiotic consumption and lost work time. Well tolerated from the clinical and laboratory points of view, it proved remarkably effective. It has been hypothesized that induction of interferon may account for the excellent clinical results obtained with SLO4, and numerous authors regard this compound as one of the basic keys to regulation of immune reactivity. Pharmacological trials under way with SLO4 should help answer this question.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004926:Escherichia coli; D005260:Female; D006801:Humans; D007711:Klebsiella pneumoniae; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000628:therapy*; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents
Immunothérapie des infections respiratoires récidivantes. Etude en double aveugle d'un nouvel immunomodulateur chez 60 patients.